Is Transpact Enter. overvalued or undervalued?

As of 23 October 2025, the valuation grade for Transpact Enter. has moved from risky to very expensive. The company is currently overvalued, as indicated by its exceptionally high PE ratio of 913.07 and a price to book value of 9.13. Additionally, the EV to EBITDA stands at 9.12, which, while not extreme compared to the PE ratio, still suggests a lack of profitability relative to its valuation.
In comparison to its peers, Transpact Enter. shows stark contrasts; for instance, Poly Medicure has a PE of 54.6 and an EV to EBITDA of 40.61, while Blue Jet Health has a PE of 31.47 and an EV to EBITDA of 24.20. Both peers are also classified as very expensive, but their ratios are significantly lower than those of Transpact Enter., reinforcing the notion of overvaluation. Despite a solid performance against the Sensex over the past year, with a return of 14.72% compared to the Sensex's 5.59%, the current valuation metrics suggest that investors should approach with caution.